BLOG
Passage of Biosecure Act gets postponed to the new administration
The enactment of US Biosecure Act, which was consummated to neutralise US dependence on few Chinese CDMO companies, is likely get delayed for want of passage in the US Senate as the government will go on recess till the new administration comes into power.
It is also likely that the modified version may exclude direct naming of the companies, instead this will provide specific guidelines for de-risking.
Since the bill was already through in the US House of Representatives in the month of September with a bi-partisan support and a clear majority, we do not expect change of stance from the new government.
However, irrespective of the passage of Biosecure Act, global companies have already started to de-risk there supply chain, specifically the China part and hence provide supply chain diversification opportunities for Indian CDMO players.
Our thesis also considers other important factors like possible opportunities emanating from the acquisition of world’s second largest CDMO player Catalent by Novo Nordisk and improvement in US Biotech funding scenario on the back of benign interest rate scenario in the US.
Most of the players have undergone significant capex expansion in recent years with the combined capex figure for Divi’s, Syngene, Piramal Pharma, Hikal and GLS stood at Rs 9600 crore during FY21-24. This capex is based on visibility built in over the years tracking supply chain diversification and not necessarily targeting the Biosecure Act which came into shape only at the beginning of 2024.
A case in point is Piramal Pharma's CDMO sales guidance of US$ 1.2 billion for FY30 (~13% CAGR) which is without considering possible windfall from Biosecure Act implications.
Our top picks in the CDMO space are PPL with a TP of Rs 280 and Syngene with a TP of Rs 1030.
Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Related content
Blogs
Articles - Stocks
Advantages and Disadvantages of NPS
It is a long established fact that a reader will be distracted by the readable content of a page when looking at it...
Articles - Stocks
Advantages and Disadvantages of NPS
It is a long established fact that a reader will be distracted by the readable content of a page when looking at it...
Articles - Stocks
Advantages and Disadvantages of NPS
It is a long established fact that a reader will be distracted by the readable content of a page when looking at it...
Video
Video - Stocks
What is Book Value?
Book Value Explained – Find out what is book value in stocks in this video by ICICIdirect.com.
Video - Stocks
What is Book Value?
Book Value Explained – Find out what is book value in stocks in this video by ICICIdirect.com.
Video - Stocks
What is Book Value?
Book Value Explained – Find out what is book value in stocks in this video by ICICIdirect.com.